Marco Meglio

More than 40% of patients with ASPECTS scores between 4 and 5 treated with EVT showed functional outcome improvements, whereas slightly over 20% of those with scores between 0 to 3 demonstrated the same.

The adult neurologist at Allegheny Health Network discussed the ever-changing landscape of therapies for myasthenia gravis and shift toward more holistic disease management.

In a phase 2 study, fosgonimeton showed positive effects on measures of cognition, function, and neurodegeneration when taken as a monotherapy, prompting an unblinded interim analysis.

EDG-5506, an orally administered small molecule agent, showed nearly a 40% decrease in levels of serum creatine kinase in a phase 1b trial of adults with Becker muscular dystrophy.

In an open-label extension trial, tofersen showed significant reductions in SOD1 protein and neurofilament light over a 12-month period. It is now expected to be reviewed by the FDA by early Q2 2023.

The launch of the medication was done in phases, as wholesalers received first-line formulary coverage in September 2022, while a nationwide launch is expected in 2023.

P100 amplitude of 15 minute checks in the NMOSD-ON group had a significant reduction at 6 months relative to the IDON group, suggesting more several axonal damage.

Over a 2-year treatment period, discontinuation rates with risdiplam were low, and observed adverse events and serious AEs resembled previously conducted studies.

Annualized relapse rates were elevated compared with the prepregnancy period, especially during the initial 3 months after delivery, whereas EDSS scores worsened during pregnancy and the postpartum period.

The odds of having memory worsening at follow-up after 3 years were almost 30% greater for those who exhibited deteriorating insomnia status than those who showed signs of improvement.

Similar to the recently commenced phase 2b LUMA study, BIIB122, an investigational small molecule inhibitor of LRRK2, will be evaluated in a cohort of 400 individuals with genetically mutated Parkinson disease.

The division chief of stroke and vascular neurology at Duke Health discussed how clinicians have typically treated poststroke motor symptoms and how technology is expanding these capabilities.

Valproic acid, which had been associated with a variety of major and minor malformations in pregnancy, remained barely unchanged in terms of use, dropping slightly from 12.4% to 10.1% over the 5-year period.

Joe Kardine, MS, OTR, CBIS, the clinical program manager at the Jefferson Center for Neurorestoration, discussed the influx of new neurorestorative technology and the future of treating patients with functional loss.

In a cohort of nearly 600,000 individuals, the combination of dementia diagnosis and presence of psychiatric comorbidity significantly increased the risk of suicide.

Enrollment for the phase 1/2 study will be partially stopped; however, all participants included in the trial, whether on AOC 1001 or placebo, are eligible to continue their current dosing regimen.

Using magnetic resonance spectroscopy, investigators observed significantly different levels of total NAA across MS and NMOSD subtypes, and a negative correlation between total NAA and disability score.

When hydromethylthionine mesylate was compared with publicly available placebo decline data, the treatment effects of cognitive and functional decline are about 3-fold larger over 18 months.

Nicholas Silvestri, MD, clinical professor at the University at Buffalo discussed topics related to the expansion of treatments for myasthenia gravis and the positive outlook of managing the disease.

The clinical program manager at the Jefferson Center for Neurorestoration discussed a new approach to restoring arm function using a powered arm brace and muscle stimulation system.

No statistical differences were found between REN and the standard of care medications, in any of the effectiveness outcomes of pain single-treatment pain relief and pain freedom, nor in consistency of pain relief and pain freedom.

Despite not meeting its primary and secondary end points, CNM-Au8 will continue to be evaluated in an open-label extension in HEALEY ALS and could potentially be offered in an expanded access protocol program.

Designed to treat the underlying cause of FSHD, AOC 1020 will be evaluated on safety, tolerability, pharmacokinetics, and pharmacodynamics in a cohort of 68 adults with the disease.

Justin Klee and Josh Cohen, cofounders and cochief operating officers, Amylyx Pharmaceuticals, answered questions related to the new approval of AMX0035 for ALS and how it changes the treatment landscape going forward.

Sleep changes experienced by patients on apomorphine infusion were indicated by scores on Insomnia Severity Index and Clinical Global Impression-Improvement Scale.

Despite not improving clinical end points, treatment with tofersen was associated with reduced in the total concentration of SOD1 protein and neurofilament light chain, a marker of axonal injury.

In additional data from CENTAUR, Amylyx touted the drug's ability to prolong tracheostomy-free and ventilation-free survival.

After previously failing a phase 3 trial of patients with multiple system atrophy, verdiperstat continued to show an effect in patients with ALS that was similar to those on placebo.

Ashgan Elshinawy, DO, a pulmonologist at Penn Medicine, assessed the current ways to treat patients with insomnia and the areas of needed improvement.

Consistent with the overall population, newly diagnosed, treatment-naïve patients with MS showed better relapse rates, all-cause disability worsening—including progression independent of relapse activity—with ofatumumab over teriflunomide.